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TO THE READER 
In Finland, all citizens are entitled to equal access to healthcare and social welfare services. 
However, equity in health care services is not always easy to achieve for people with rare 
diseases. Their diseases may be difficult to identify, specialists may be few, there are no 
effective treatment methods, or the available level of evidence for efficacy may be low.
The first Finnish National Programme for Rare Diseases 2014-2017 followed the 
recommendations of the Council of the European Union. The programme detailed a plan 
for various necessary actions, but not all of its objectives were accomplished. Over the past 
few years, the operational environment in which rare diseases are treated has changed 
considerably for a variety of reasons, such as the establishment of European Reference 
Networks. Therefore, it was time to revise the programme.
Three main themes have been highlighted in the revised National Programme for Rare 
Diseases: the involvement of people with rare diseases, augmenting expertise and 
strengthening coordination. These themes are examined at different levels of the Finnish 
service system. This Programme is not a detailed action plan, but it rather outlines the 
general direction for decision-makers and people working with rare diseases, who on 
their behalf are responsible for the measures and monitoring of this programme during its 
implementation.
The programme aims at enhancing the involvement of people with rare diseases in 
decisions concerning themselves, and at intensifying collaboration of rare disease patient 
organisations in improving healthcare and social welfare. Other key objectives include 
providing up-to-date and correct information in a manner that is easy to understand, and 
reinforcing competence in healthcare and social welfare. The expertise provided by the 
European Reference Networks will likely improve the availability and quality of diagnostics 
and care. Promoting cooperation between different parties will improve regional and 
national coordination. To successfully implement coordination, programme calls for 
nationally agreed division of tasks.
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The National Programme was drafted in the Sub-Committee of the Working Group on Rare 
Diseases, established by the Ministry of Social Affairs and Health. We would like to thank 
the Sub-Committee for its invaluable work. The Programme was edited by a representative 
of the Finnish Network for Rare Diseases, Risto Heikkinen from the Finnish Federation for 
Allergy, Skin and Asthma. All key stakeholders have commented on it before publication.
It is of paramount importance that all parties working with rare diseases commit 
themselves to the implementation of this Finnish National Programme for Rare Diseases 
2019-2023.
July 2019
Working Group on Rare Diseases
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1 Introduction
Approximately more than 300,000 Finns have a rare disease, disability, syndrome 
or malformation. There are thousands of rare diseases and they are highly variable. 
Some present in childhood, others only at the adulthood. A rare disease may be barely 
noticeable or cause severe impairment.
There are between 6,000 and 8,000 known rare diseases with new described constantly in 
medical literature. In Europe, the definition of rare diseases covers diseases that affect no 
more than 5 in 10,000 people. In Finland, this implies 2,800 individuals per disease at most. 
Approximately, over 300,000 Finns or about six per cent of the population have some kind of 
rare disease, disability, syndrome or malformation. Rare diseases are a very heterogeneous 
group of illnesses. Some rare diseases are diagnosed soon after birth, others not until 
adulthood. Some of these progress in severity, while others do not. Sometimes a sub-form of 
a common disease may be rare. Therefore, one should consider the person’s own evaluation 
of his or her status and outcome and the challenges related to it.
There are strong justifications for updating the National Plan for Rare Diseases and setting 
new targets and action proposals. In an extensive European survey (Eurordis 2017), more 
than 50% of people with rare diseases and their families reported that the disease had 
serious or very serious impacts on their everyday life, such as on their ability to cope with 
everyday routines or personal care. The UN Convention on the Rights of Persons with 
Disabilities from 2006 was ratified in Finland in 2016 and has influenced our legislation, 
the patient’s and the customer’s status, and the healthcare and social welfare practices in 
Finland. The Convention emphasises the importance of strengthening the involvement 
and right to self-determination of people with disabilities and chronic diseases. This also 
improves the status of people with rare diseases as users of the service system.
The costs incurred by rare diseases in specialised medical care highlight the need to 
update the National Programme for Rare Diseases and set new objectives.
According to a survey concerning the period 2010-2014, individuals with rare diseases 
accounted for between 6% and 8% of patients receiving specialised medical care in 
the Hospital District of Helsinki and Uusimaa and the Northern Ostrobothnia Hospital 
District. However, the costs related to rare diseases in specialised medical care in these 
two hospital districts were slightly under 20% of the overall costs of specialised medical 
care. This estimate did not include the costs of rehabilitation, social services or outpatient 
healthcare. For example, costs result from delays and failures of diagnostics or appropriate 
treatment. The methods used in diagnostics and treatment of rare diseases may also be 
expensive.
11
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In 2014, the Working Group on Rare Diseases established by the Ministry of Social Affairs 
and Health compiled a proposal for the Finnish National Programme for Rare Diseases. The 
programme was based on the recommendation issued by the Council of the European 
Union in 2009, which obligated the Member States to strengthen their plans and strategies 
for rare diseases. Finland’s National Programme described the plight of individuals living 
with rare diseases and the challenges they faced. It presented 16 general objectives and 13 
concrete proposals for the development of research, care, rehabilitation and social support 
for people with rare diseases. The programme period ended at the end of 2017. The term of 
the Working Group on Rare Diseases promoting the implementation of the National 
Programme ended at the same time. Thereafter, the working group was granted an 
extension from January 1st 2018 to December 31st 2019 with the following tasks to:
The preparation and implementation of the tasks were given to the Sub-committee set 
up by the Working Group. In spring 2018, the Working Group decided to update the 
National Plan for a four-year period, as proposed by the Sub-Committee. Risto Heikkinen, 
a member of the working group, was chosen for the task of coordinating the update 
and writing the revised programme. Individuals with rare diseases, their families and 
key professionals from the field of rare diseases were involved in the update. A survey 
to organisations and associations representing rare diseases was conducted during 
autumn 2018. A patient advocacy group (Harkko) and other member communities of the 
Finnish Network for Rare Diseases (www.harvinaiset.fi), consisting of 21 social and health 
organisations, were in various ways involved in evaluating the implementation of the first 
National Programme and in updating it. In addition, a survey to the five Rare Disease Units 
in university hospitals and to the 14 Finnish healthcare provider members of ERN networks 
was conducted. The discussions and results from the national conference on rare diseases 
1. Define and draw up a proposal for strengthening national coordination in the 
field of rare diseases.
2. Assess the need to update the National Programme for Rare Diseases and plan 
the update.
3. Monitor the operation of European Reference Networks in Finland.
4. Monitor and promote the cooperation between the Rare Diseases Units in uni-
versity hospitals and the implementation of tasks laid down in the Government 
Decree on the Division of Work in Specialised Medical Care and Centralisation 
of Certain Tasks (582/2017).
5. Support the operation of the Nordic Network on Rare Diseases.
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organised in October 2018 further complemented the programme. Before its finalisation, 
the updated draft programme was sent to the stakeholders for comments.
The revised plan provides a general overview of the current situation, evaluates the 
progress made in the implementation of the actions proposed in the old programme and, 
based on this, proposes new actions. The purpose of the programme is to develop the 
social and healthcare service system to better meet the needs of people with rare diseases. 
In addition, the intention is to promote the daily coping abilities of people with long-term 
illnesses and disabilities, who during their lives face similar challenges to people with rare 
diseases.
The revised programme emphasizes the importance of expertise, involvement and 
coordination. It aims at improving the position of people with rare diseases, and the 
ability of their families, friends and themselves to cope in their daily lives by speeding 
up the diagnosis and promoting their access to high-quality care and rehabilitation. The 
objectives for the upcoming programme period are to increase the amount of up-to-date 
and correct information, to reinforce expertise and to promote cooperation between 
different parties by strengthening national coordination. The specialist expertise and 
the tools provided by the European Reference Networks are a new way of improving the 
availability and quality of diagnostics and care. Integration of the Reference Networks into 
the Finnish service system requires cooperation and descriptions of care pathways. To 
implement the coordinating tasks in practice, division of work also needs to be agreed at 
the national level.
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2 Implementation of programme 
objectives in 2014-2017 and changes in 
the operational environment
General awareness of rare diseases increased during the first programme period. 
The Units for Rare Diseases and regional coordination were launched, with new 
centres of expertise at university hospitals. Cooperation at the Nordic and European 
levels increased. Nevertheless, many objectives were only partially implemented 
while changes in the operational environment lead to identification of previously 
unrecognized demands.
Thirteen actions were proposed for the programme period 2014-2017 to promote the 
definition and registration of rare diseases, research, improved and more efficient 
healthcare, coordination of expertise, knowledge sharing, provision of holistic support for 
individuals with rare diseases, and strengthening their involvement.
 PROPOSED ACTIONS 2014–2017
•  Adopting a uniform definition for rare diseases and acknowledging the need  
 fordedicated measures
•  Establishing a national registry for rare diseases 
•  Focused research funding and research programme for rare diseases
•  Strengthening of international research collaboration
•  Streamlining the care pathway for an individual with rare disease 
•  Establishing Units for Rare Diseases in all university hospitals 
•  Establishing specialized Centres of Expertise for Rare Diseases
•  Providing more education and training
•  Promoting the availability of orphan drugs
•  Establishing a national coordinating centre for rare diseases
•  Systematic collection and sharing of information
•  Developing social support and rehabilitation
•  Augmenting rare disease patient involvement 
14
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Implementation of the proposed actions has not comprehensively been evaluated. 
Docent Ilona Autti-Rämö, a member of the Working Group on Rare Diseases, presented 
observations on the first National Programme and its implementation at the National 
Conference on Rare Diseases held in spring 2017. According to her estimate, the only fully 
implemented actions were the adoption of a uniform definition for rare diseases, and the 
establishment of Rare Diseases Units and Centres of Expertise for rare diseases. The other 
proposed actions had progressed variably.
EU Member States share the need to develop the diagnostics, care and expertise related 
to rare diseases, as no single country will be able to improve the situation of people with 
rare diseases on its own. International and Nordic Cooperation has indeed strengthened 
considerably between authorities, social welfare and healthcare professionals, and patient 
organisations, although the measures proposed in the first programme only emphasised 
the importance of internationalisation in the research community.
Our impression is that for the last few years the concept of rare diseases has become 
better understood, probably at least partly due to the first National Programme. In 
the following section, the implementation of the proposed actions in each area of the 
programme will be assessed in detail.
 OBSERVATIONS ON THE IMPLEMENTATION OF THE FIRST PROGRAMME  
 OBJECTIVES:
- on a general level, the programme strived towards the identification of   
 development areas and recording the challenges affecting the life of individuals  
 suffering from rare diseases 
- the implemented actions were those that were achievable by developing or   
 changing existing operations
- the measures requiring national agreement have been implemented only   
 partially
- as of now, the needs of individuals with rare diseases have been insufficiently  
 acknowledged in legislation to for example enable equitable care pathways
- actions requiring new resources, or redivision of resources or funding, were   
 largely not implemented
15
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2.1 Adopting the definition of rare diseases and 
acknowledging the need for dedicated measures 
Finland has now put to use the European definition for rare diseases, according to which 
a disease is rare if it affects no more than 5 in 10,000 people. Like the first National 
Programme for Rare Diseases, this programme uses the concept of rare diseases to also 
refer to rare disabilities, malformations and symptoms.
The legal status of people with rare diseases has been addressed in legislative 
amendments, government bills concerning the health and social services reform and 
in the background material for the reform. An Act amending the Health Care Act 
(1516/2016), which entered into force in 2017, made section 45 of the Health Care 
Act (1326/2010) more specific, with an obligation to centralise certain medical tests, 
procedures and care requiring highly specialised expertise to fewer than five university 
hospitals. The Government Decree on the Division of Work in Specialised Medical Care and 
Centralisation of Certain Tasks (582/2017) obligates the five hospital districts maintaining 
a university hospital to perform, plan and coordinate certain tasks in specialised medical 
care regionally. The prevention, care, diagnostics and rehabilitation of rare diseases are 
part of this obligation.
The ratification of the UN Convention on the Rights of Persons with Disabilities in 2016 
improves the status of people with disabilities by prohibiting all kinds of discrimination 
against them. The Convention emphasises the human rights and equity of people with 
disabilities and requires that people with disabilities and the organisations representing 
them to be included in the planning and decision-making concerning them. The principles 
described in the Convention also touch on the position of individuals with rare diseases, 
The Convention emphasises the importance of the accessibility of the physical, social and 
mental environment. For example, ensuring equal access to information and interaction 
are an important part of accessibility.
2.2 Units and centres of expertise for rare diseases
The establishment of Rare Diseases Units in all five university hospitals and the membership 
of a total of 14 centres of expertise from four university hospitals as healthcare provider 
representatives in the European Reference Networks for Rare and Low Prevalence Complex 
Diseases (European Reference Networks, ERN) have been important reforms in promoting 
the diagnostics and treatment of individuals with rare 
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diseases. The status of Rare Diseases Units (and/or Centres) has been strengthened 
with the Governmental Decree on Centralization of Specialist Health Care and Some 
Other Actions (582/2017). For their part, these measures have improved the status and 
involvement of individuals living with rare diseases. The importance of the status and tasks 
of these units and centres is emphasised in the objectives and proposed actions of this 
National Programme.
To implement the health sector growth strategy, four National Centres of Excellence that 
have been highlighted as key strategic focus areas are in the process of being established 
in Finland. The goal of a project entity aimed at better utilisation of genomic data is to 
establish a national Genome Centre. Legislation in the use of 
genomic data and legislative clarification of the status of biobanks is currently in 
preparation. Among other things, biobanks collect and store biological samples for rare 
disease research. In addition to five regional cancer centres, a national cancer centre 
(Comprehensive Cancer Centre Finland, FICAN) has started in 2019 while the 
establishment of a Neurocentre Finland is in preparation. These projects will improve the 
operating conditions of personalised medicine in healthcare. Personalised medicine plays 
an important role also in the treatment of rare diseases.
2.3 Research funding and research cooperation
Finland has conducted no comprehensive study of research focusing on rare diseases. 
According to the estimate by the Academy of Finland in 2017, the Academy’s Research 
Council for Biosciences, Health and the Environment had granted just over EUR 20 million 
to 57 research projects focusing or touching upon rare diseases between 2011 and 2017. 
Excluding research in rare cancers and infectious diseases, the overall funding for research 
in rare diseases was EUR 19 million. This is less than 10% of funding from the Research 
Council. Of the 24 rare disease groups included in the ERNs, 10 research fields remained 
completely unsupported during the time of the estimate, despite internationally effective 
research in many of them. These disease groups include also diseases enriched in Finland.
There are other funding sources for research conducted on rare diseases in ERN centres 
and universities. In the total funding, the importance of short-term funding from research 
foundations has increased while – due to cuts in government research funding – the number 
of research personnel has reduced and fewer research equipment updated. Research 
focusing on the genetics and epigenetics of rare diseases requires that genomic variation 
be reliably and precisely determined, especially in populations with a narrow genetic base. 
17
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A significant part of scientific research in rare diseases also focuses on patients identified 
during clinical practice in university hospitals and on the ensuing translational studies 
collaboratively carried out by the clinician and basic researchers. In such studies, continuous 
governmental research funding granted to hospital districts plays a vital role.
In 2013, the Academy of Finland joined the International Rare Diseases Research 
Consortium IRDiRC (www.irdirc.org). The consortium brings together actors whose 
work involves rare diseases research. Furthermore, the Academy has participated in the 
European E-RARE-3 research funding cooperation between 2017 and 2018. In 2019, a 
five-year funding project by the European Commission, the European Joint Programme 
on Rare Diseases (EJP RD, www.ejprarediseases.org) will be launched. The objective 
of this project is to improve the quality of life for individuals with rare diseases by 
increasing knowledge about the diagnostics, treatment and care of rare diseases. The 
project brings together research sponsors, research institutes, universities, university 
hospitals, ERN Centres of Expertise and patient organisations. The Academy of Finland has 
participated in this from its beginning. Rare diseases have been the object of international 
clinical pharmaceutical research projects, while Finland’s participation in them, and in 
pharmaceutical research in general has declined.
2.4 Disseminating information and strengthening knowledge
The main yield of the joint Virtual Hospital 2.0 project (2016-2018) of the five university 
hospitals, funded by the Ministry or Social Affairs and Health, is Health Village, a web 
service of special health care (www.terveyskyla.fi). It provides information and support 
for different diseases, symptoms and life situations in Finnish and Swedish (hälsobyn.fi). 
Health Village contains a hub providing information on rare diseases (harvinaissairaudet.
fi, sällsyntasjukdomar.fi), with sections open to all and exclusively to professionals. On its 
open web pages, information on rare diseases in 10 different disease groups has thus far 
been made available. Also, information on health and social services has been compiled 
on the website. Further, information on six rare disease groups can be found in the 
other hubs of Health Village. Additional information in Finnish related to rare diseases 
is available on the Finnish websites of Orphanet, in Terveysportti and Terveyskirjasto 
maintained by Duodecim, and on the homepages of the Finnish Network for Rare 
Diseases, containing information produced by patient organisations and associations.
The Rare Diseases Units have organised training for healthcare professionals in their 
own specific catchment areas. Rare diseases have been introduced in medical journals, 
at physician’s seminars in different regions and at conferences and events organised by 
different stakeholders. The Nordic Conference on Rare Diseases was held in Finland 2014. 
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Finnish actors from the field of rare diseases have participated in the Nordic Conference 
on Rare Diseases in Copenhagen in 2016 and in the 
conferences of Eurordis (www.eurordis.org), a European umbrella organisation of rare 
disease organisations. Eurordis conferences are held every two years; the most recent one 
was held in May 2018 in Vienna. Finland also participates in the Nordic Network on Rare 
Diseases aimed at promoting Nordic cooperation in the field of rare diseases. The network 
is funded by the Nordic Council of Ministers. The network of Nordic patient organisations 
(Sällsynta Brukerorganisationers Nordiska Nätverk, SBONN) promotes cooperation 
between groups representing people with rare diseases.
2.5 National registry for rare diseases and streamlining of 
care pathway
Establishing a National Rare Diseases Registry has been promoted through cooperation 
between the National Institute for Health and Welfare (THL) and the Rare Diseases Units 
in university hospitals. The Orpha nomenclature, based on the diagnosis database of the 
European Orphanet website (www.orpha.net) collecting data on rare diseases will be 
integrated with the Finnish code server parallel to the ICD-10 disease classification. The 
codes will make the identification of rare diseases easier. There are also plans to make 
Orpha codes a part of the Care Register for Health Care (Hilmo). A project to design alerts 
for those rare diseases in which special vigilance or expertise is required from healthcare 
professionals is ongoing; such alerts should be implemented into all electronic patient 
record systems in use.
To enhance the diagnostics, care and rehabilitation of rare diseases and to promote service 
provision, information about these has been made available in the professional section 
of the Health Village rare diseases hub. However, adequate information on available rare 
disease rehabilitation and social welfare services covering all levels of the service system is 
still lacking. The ERNs have started to produce information and guidance on the treatment 
of rare diseases. These can also be used nationally.
2.6 Social support, rehabilitation and augmentation of 
involvement
After the publication of the first National Programme, special health care has seen 
progress that significantly has enhanced the care of rare diseases. New practices and 
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operating procedures have been created to facilitate and promote the diagnostics and 
adequate treatment of rare diseases. Still, many individuals with rare diseases remain 
without appropriate needs assessment in which for example the functional challenges 
in their daily life and the factors affecting their income would be taken into account. Not 
everyone with rare diseases may enjoy the benefits of multiprofessional work. Although 
representatives with rare diseases have been chosen to steering groups of Rare Diseases 
Units, first programme’s proposals regarding strong involvement of patient groups in the 
planning and evaluation of centres of expertise and in the establishment of customer 
panels have not been implemented sufficiently. Increasing and more systematic efforts are 
required to involve representation of people with rare diseases, their families and patient 
organisations in the planning and evaluation of care and services.
2.7 National coordinating centre for rare diseases
The national coordinating centre proposed in the first National Programme was not 
implemented. In the course of the programme period, the importance of coordination 
in promoting the objectives of the National Programme and of implementing 
equitable treatment for people with rare diseases has only become more prominent. 
The responsibilities of regional coordination of rare disease activities belongs to 
university hospitals, but the need for national coordination extends widely over various 
stakeholders. Until now and partly randomly, coordination has relied on the Ministry of 
Social Affairs and Health, on unofficial cooperation between Rare Diseases Units, and 
active operators in the third sector. In coming years, there is a need for clarification of the 
roles and coordination tasks of different authorities. The present Programme introduces 
the active operators participating in such coordination, the coordination tasks, and 
includes proposals for further development of coordination. The Ministry of Social Affairs 
and Health and the Working Group on Rare Diseases will continue the work to define 
necessary coordination structures during 2019.
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3 Pivotal objectives of the National 
Programme 2019–2023
The pivotal objectives of the National Plan 2019-2023 are to increase expertise and 
its communication, to build up involvement of patients with rare diseases in decision-
making concerning them, and to establish national coordination firmly. Resources 
are needed also for scientific research on rare diseases with special emphasis on the 
Finnish disease heritage.
3.1 Increasing knowledge on rare diseases and strengthening 
expertise
Knowledge and expertise in rare diseases is unevenly distributed and occasionally difficult 
to find. A person with rare disease may know more about her or his disease than a health 
professional. The importance of experiential knowledge on rare diseases is highlighted 
by the lack of medical knowledge. Due to lack of knowledge, unusual combinations of 
symptoms and findings may not be identified as a rare disease. Diagnostic delays may 
impair the implementation of effective treatments and rehabilitation. Furthermore, 
insufficient expertise of health professionals to advise and direct a person with rare 
diseases to employ necessary aids and services may increase the costs of social welfare 
and healthcare. Since information may be hard to come by, centralisation of available 
information and expertise would improve accessibility.
Strengthening rare disease expertise and increasing accessibility of information provide 
ways of improving the diagnostics and care of rare disease patients. As part of cross-
border healthcare, increasing the availability of information and expertise in rare diseases 
has been entrusted to European Reference Networks (ERNs). In addition to the ERN 
healthcare providers, further units and centres of expertise in rare diseases also operate in 
hospital districts. To find best available expertise, nationwide cooperation and sharing of 
information will be pivotal. Critically, scientific research increases expertise and makes the 
development of new treatments possible.
3.1.1 Increasing knowledge and awareness
Patient organisations and foundations have traditionally produced information targeted at 
individuals living with rare diseases, and their families. Experiential knowledge is collected 
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both nationally and internationally. Eurordis maintains the Rare Barometer Voices website 
(www.eurordis.org/voices), By registering on it, one can respond to surveys on healthcare 
and social welfare experiences and on everyday challenges met by people with rare 
diseases. The Finnish Network for Rare Diseases and rare disease patient organisations in 
various ways collect experiential knowledge gained to help identify problem areas in the 
service system and to develop solutions.
Table 1. Information on rare diseases on websites (in Finnish and Swedish):
Health Village, rare 
diseases
www.harvinaissairaudet.fi sällsyntasjukdomar.fi, a national 
website providing information on rare diseases, targeted at 
the general public and professionals
Duodecim, 
Terveysportti and 
Terveyskirjasto
www.terveysportti.fiwww.terveyskirjasto.fi, the website of the 
Finnish Medical Society Duodecim, targeted at the general 
public and professionals
Orphanet
www.orpha.net/national/FI-FI/index/kotisivu/, an open website 
with comprehensive  
information on rare diseases and orphan drugs
Finnish Network for 
Rare Diseases
www.harvinaiset.fi, a website compiling and communicating 
information on rare diseases by organisations and associa-
tions
National Institute for 
Health and Welfare 
(THL)
www.thl.fi/fi/web/vammaispalvelujen-kasikirja, Handbook on 
Disability Services, an open website containing
information related to the life of people with disabilities and 
available services
The rare diseases hub in Health Village provides information to individuals with rare diseases, 
their families and professionals.
Ultimately, the responsibility for generation of information on rare diseases lies with the 
public sector. The development of the rare diseases hub in Health Village to meet the 
needs of individuals with rare diseases, their families and professionals will be vital. During 
development, other reliable sources of information on rare diseases should be taken into 
account by linking, whenever possible.
In addition to open data, Health Village has a dedicated section for healthcare and social 
welfare professionals. This section contains information on disease diagnostics and 
treatment, and on care and service pathways. To further support consultation and referral, 
it has a search function to find rare disease experts. The Rare Diseases Units participate in 
the production of information to it. 
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It will be possible to develop the rare diseases hub in Health Village into a versatile 
information portal for rare diseases in cooperation with different operators. This will make 
it easier to find and take advantage of information in Finnish.
Care instructions and descriptions of service pathways
As there are very few evidence-based clinical practice guidelines for rare diseases, guidelines 
for diagnostics, care and service pathways should be formed through cooperation and 
consideration the experience gained by different operators. The European Reference 
Networks (ERNs) produce information on the diagnostics and treatment of diseases in 
their own disease groups and promote rare disease-focused scientific research. The Finnish 
centres of expertise participate in this. Such information should be utilised when creating 
national practices. Medical information is supplemented with information about social 
welfare services on disease- or disease group-specific basis. General knowledge about social 
welfare services does not always suffice when services for an individual with rare disease are 
designed. The Health Village hubs for rare diseases and rehabilitation (www.kuntoutumistalo.
fi) contain information on social welfare services, among other things.
The care and service pathways of people with rare diseases vary according to disease 
characteristics and the person’s life situation. To better enable people with rare diseases 
to timely receive the needed treatments, individualized care and service pathways should 
be designed. Such a pathway describes the key procedures, issues and operators for 
which individuals’ needs should be considered and availability ensured while organising 
their care and services. For the largest and especially challenging groups of rare diseases, 
on top of general descriptions diagnostic and care instructions which include general 
quality requirements and list special challenges at different stages of the care and service 
pathway will be needed. Such pathway descriptions should be delineated in collaboration 
with patient organisations and networks. The challenges in everyday life vary between 
different rare diseases. One therefore will need to describe in disease-specific ways how 
coping with everyday life could be supported best. The nature of social support needed 
will likely vary in different rare diseases.
The Orphanet website provides information on the most common rare diseases in Finnish
The open access Orphanet website (www.orpha.net) is a joint project of 40 countries. 
The website is funded by the EU and it is open to everyone. Presently, Orphanet contains 
information on approximately 6,100 rare diseases, related research projects and services 
(patient organisations, centres of expertise, laboratories) and orphan drugs. In addition, 
Orphanet maintains Orpha coding, the most comprehensive classification of rare diseases 
available. Norio Centre of Rare Diseases is currently responsible for adding Finnish 
information about rare diseases to Orphanet service.
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The introductory pages of Orphanet database and approximately 200 article summaries on the 
most common rare diseases have been translated into Finnish. Currently available resources are 
insufficient to translate and maintain the entire database. In future, Orphanet will seek 
cooperation with ERN networks and other information producers on rare diseases in its 
production of information. To ensure the continuity of the Orpha nomenclature, EU is looking 
for ways to commit the Member States to providing stronger support for Orphanet. Orphanet 
funding needs to be regularised in Finland as well. To avoid overlapping work, it is important to 
coordinate between the information contained in Orphanet and the contents of Health Village.
The website of the Finnish Network for Rare Diseases contains information produced by patient 
organisations
 OBJECTIVES AND PROPOSED ACTIONS IN RARE DISEASES
 −  increasing cooperation between website administrators producing information (e.g. 
Duodecim, Health Village, National Institute for Health and Welfare (THL), Finnish 
Network for Rare Diseases (FNRD), Orphanet) to improve the availability and cover-
age of information in Finnish and Swedish, and to avoid overlap
 − developing the content of the open hub of rare diseases in Health Village in 
ooperation with representatives of Rare Diseases Units, stakeholder organisations 
and associations
 − increasing experiential knowledge reported by people with rare diseases (PROM, 
PROMIS) through cooperation between THL, development personnel of healthcare 
units and patient organisations.
 − by regular surveys conducted by patient organisations assess and monitor the 
everyday challenges of individuals with rare diseases and flexibility of their care 
pathways 
 − improving and expanding related information on available social welfare, aids, 
services and guidance, and advice about its availability, in collaboration with THL, 
the Social Insurance Institution of Finland (Kela), Health Village and FNRD
 − disseminating information on and increasing awareness of rare diseases, and 
organising training in cooperation with different operators in the field 
 − sharing through Health Village the patient information and instructions produced by 
the European Reference Networks (ERN) in Finnish and Swedish 
 − ensuring continued Orphanet activities in Finland
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People with rare diseases need information in their own language. For several decades, 
organisations in the field of healthcare and social welfare have produced rare disease-
related information. Materials produced by the member communities of Finnish Network 
for Rare Diseases have been linked to the network’s website (www.harvinaiset.fi ). 
Currently, the website carries or links to information in Finnish on about 300 rare diseases, 
together with further rare disease-related information, This includes contact details of 
relevant associations or interest groups and advice on available services and peer support. 
Adding such information systematically to other databases, especially to the rare diseases 
hub in Health Village, would be recommendable.
3.1.2 Strengthening the status of Rare Diseases Units and allocation of 
resources to them
In accordance with the Government Decree on the Division of Work and Centralisation 
of Certain Tasks (582/2017, section 4), rare diseases units were established in each of the 
five university hospitals, between 2015 and 2017. A physician in charge and a healthcare 
professional with background in nursing work in each unit.
Table 2. Units for rare diseases and their personnel resources 2019
Unit Established Physician in charge Other personnel
HUS (HAKE) 1 January 2015 physician 100% nurse 100%
TYKS 1 January 2016 physician 100% nurse 20%
KYS (HARSY) 1 February 2016 physicians jointly 50% nurse 100%
OYS (Harvi) 2 June 2016 physician 30% nurse 100%
TAYS (HarSY) 1 January 2017 physician 60% nurse 100%
The Rare Diseases Units (Centres) have developed at different paces, according to their 
resources. To promote equity at the national level, it will be necessary that the basic tasks 
of the units be determined in a uniform manner, to further delineate the obligations 
laid down in the Centralisation Decree. However, due to regional and hospital-specific 
differences, unit activities include different tasks and focus areas.
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The standardization of basic tasks may require stronger resources and harmonised acti-
vities. Description of uniform contact and referral practices will be needed. Information 
about various tasks of Rare Diseases Units should be made available to individuals with 
rare diseases, their families and healthcare and social welfare professionals. The units have 
advocated increased awareness and information about rare diseases in their specific ca-
tchment areas by for example organising training to professionals. In their areas, the Rare 
Diseases Units play important roles in promoting understanding on the need for heal-
thcare and social welfare services by people with rare diseases 
 THE BASIC TASKS OF RARE DISEASES UNITS (CENTRES) IN THEIR   
 SPECIFIC CATCHMENT AREAS:
 − facilitating the development of clear care and service pathways
 − participation in the coordination of the diagnostics and care of people with 
rare  
diseases, and of associated referral practices 
 − providing a consultation service to healthcare and social welfare professionals 
 − general advisory services and guidance for people with rare diseases to 
suitable  
care or service pathways
 − increasing information and awareness of rare diseases
 − promoting research in rare diseases
 − cooperation with different healthcare units, authorities and organisations
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Pivotally, the regional roles of Rare Diseases Units should be strengthened according to 
the Centralisation decree. Mutually cooperatively, national practices such as electronic 
consultations and descriptions of service pathways should be developed between the 
units. Rare Diseases Units will disseminate information about the centres of expertise and 
ERN centres (healthcare providers) in their area and will need to agree on the division of 
responsibilities and tasks, regionally and nationally. 
3.1.3 European Reference Networks (ERN)
In 2014, the European Commission set up criteria according to which a healthcare unit can 
apply to the European Reference Networks (European Reference Networks for Rare and 
Low Prevalence Complex Diseases, ERN; https://ec.europa.eu/health/ern_en). The catalyst 
for establishing ERNs was the EU Directive (2011/24) on the application of patients’ rights in 
cross-border healthcare. Aims of ERNs were to empower choices to care pathways, 
organise joint training and consultations, and to enable cross-border discussions on 
the situation of a person with rare diseases without need to travel to another country, 
 OBJECTIVES AND PROPOSED ACTIONS FOR RARE DISEASES UNITS IN  
 THEIR CATCHMENT AREAS
 − in all university hospitals, ensuring the allocation of resources to Rare 
Diseases Units and consolidating their tasks and positions 
 − building up the knowledge base: a physician in charge and a healthcare 
professional with background in nursing will be needed and need to be 
familiar with rare diseases; it should be possible to consult a social worker
 − supporting the centres of expertise and units possessing expertise in rare 
diseases; sharing information on available rare disease specialists
 − supporting ERN members, facilitating ERN activities together with 
strengthening national and international cooperation and exchange of 
information
 − involving the representatives of people with rare diseases in the activities of 
the unit and the university hospital to promote customer-oriented approaches
 − communicating information on rare diseases and on unit’s activities in 
cooperation with patient organisations and networks
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apart from few exceptional cases. Expertise in each network relates to its specific group 
of rare diseases. Eurordis, an umbrella organisation of European rare disease patient 
organisations, participated in establishing criteria for ERN healthcare providers (www.
eurordis.org). Strengthening of patient involvement in the operations of ERNs and its 
healthcare providers was among the objectives.
In 2017, 24 networks started their operations in Europe. More than 900 different 
healthcare providers from 25 Member States and Norway participate. In 2018, 14 units 
from four Finnish university hospitals are members of 12 different European Reference 
Networks (ERN). Active participation in the ERNs by Finnish university hospitals will 
promote expertise in rare diseases and development of patient care. Aim will be to have at 
least one university hospital representative in each reference network.
 OBJECTIVES AND PROPOSED ACTIONS:
 − nationwide, to define the duties and responsibilities of ERN centres, to create 
cooperation practices between an ERN and other operators in its field of 
expertise, to integrate ERNs into the national service system
 − Finland’s participation in all 24 ERNs, either as a healthcare provider or an 
affiliated partner
 − with Rare Disease Units, to communicate up-to-date information about ERN 
centre operations to other actors in healthcare and social welfare 
 − in collaboration with Rare Disease Units, to strengthen the role of patient 
organisations and representatives in the ERN application process and 
operations 
 − agreeing on the assessment and monitoring of the national integration and 
other activities of the ERN centres at the national level
 − to develop Nordic cooperation of ERN healthcare providers and to participate 
in the development of European registries in cooperation with the National 
Institute for Health and Welfare (THL) and Rare Diseases Units 
 − to ensure necessary resources and support functions for ERN healthcare 
providers to participate in ERN activities
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Based on the Treaty on the Functioning of the European Union, the content of healthcare 
services and the reimbursement of costs caused by them are subordinate to decision-
making of the Member States. This also applies to medicinal products granted an EU-wide 
marketing authorisation in a centralised procedure. The Member States are not directly 
and legally bound by results of the work carried out by the European Reference Networks. 
Table 3. ERN member centres in Finland and elsewhere in Europe.  
Reference: Kääriäinen Helena, Lääkärilehti 24-31/2018 Vol. 73, p. 1580.
ERN and its subject area Finnish
centre of exper-
tise
Centres
/countries
total
ERN BOND: rare bone disorders - 39/9
ERN CRANIO: craniofacial anomalies; rare ear, nose and throat disorders HUS 29/11
Endo-ERN: rare endocrine conditions - 71/19
ERN EpiCARE: rare epilepsies KYS 27/13
ERKNet: rare kidney diseases HUS 37/12
ERN-RND: rare neurological diseases – 32/13
ERNICA: rare inherited and congenital anomalies HUS 20/10
ERN LUNG: rare lung diseases – 60/12
ERN Skin: rare skin diseases HUS 56/18
ERN EURACAN: adult rare tumour cancers TYKS 65/15
ERN EuroBloodNet: rare haematological diseases – 66/15
ERN eUROGEN: rare urogenital diseases – 29/11
ERN EURO-NMD: rare neuromuscular diseases TAYS 45/14
ERN EYE: rare eye diseases – 29/13
ERN GENTURIS: rare genetic tumour risk syndromes TYKS 23/12
ERN GUARD-HEART: rare diseases of the heart HUS 24/12
ERN ITHACA: congenital malformations and rare intellectual disability HUS 36/13
MetabERN: hereditary metabolic disorders – 68/17
ERN PaedCan: paediatric cancer TYKS,
TAYS, KYS
57/18
ERN RARE-LIVER: rare hepatological diseases – 28/11
ERN ReCONNET: rare connective tissue and musculoskeletal diseases – 25/8
ERN RITA: rare immunodeficiency, autoinflammatory and autoimmune diseases – 24/10
ERN TRANSPLANT-CHILD: transplantation in children – 17/10
VASCERN: rare vascular diseases HUS 32/11
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3.1.4 Promoting research
Research enables the development of more specific diagnostics and new treatments in 
rare diseases. Essential knowledge on the prognoses of rare diseases, on their treatment 
options, associated diseases and effectiveness and necessity of screening for these 
is lacking. Even less information is available on issues related to rare diseases like the 
extent of decline in the quality of life, on the efficiency of non-pharmaceutical therapies, 
on the burden to healthcare and social welfare or the total costs of rare diseases to 
people suffering from them and to their families. Some of these rare diseases are a part 
of the Finnish Disease Heritage, while novel and rare inherited diseases, which are less 
prominently concentrated in our population are being discovered constantly. There is dire 
need for comprehensive research data on the total burden to society and to individuals 
caused by these diseases.
While Finnish researchers participate in many international research projects, the greatest 
challenge to Finnish rare diseases research has become that researchers move abroad to-
wards better funding opportunities, mainly to other Nordic, Central European or Northern 
American countries. The establishment of the European Reference Networks will likely 
increase international research cooperation. However, any Europe-wide research funding 
potentially received will often be divided between multiple centres in different countries. 
It will be especially challenging to obtain European research funding for diseases specifi-
cally enriched in Finns. Funding of rare diseases research should therefore remain a focus 
area in national funding.
Rare diseases research is important not only to augment knowledge on rare diseases but 
also to understand the development of common non-communicable diseases. By provi-
ding unique information on the normal functioning of the human body at molecular level, 
rare diseases research enables us to model disturbances in the function of the organs and 
cells and to pinpoint pathogenetic mechanisms in more common diseases.
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 OBJECTIVES AND PROPOSED ACTIONS IN RARE DISEASE RESEARCH
 − to keep rare diseases research as a focus area in national research funding
 − to emphasise the importance of research on diseases concentrated in Finland, on 
their treatment and total burden to society and an individual
 − to keep top-notch research in Finland, increasing governmental research funding 
for high-quality studies on rare diseases 
 − targeted funding for the study of research methods used in rare diseases research
3.2 Strengthening of patient involvement in rare diseases
The UN Convention on the Rights of Persons with Disabilities from 2006 obligates Finland 
to support and promote the involvement of people with disabilities or chronic illnesses 
in matters concerning them. In addition, the Convention obligates to empower patient 
organisation involvement at various levels and the involvement of people with disabilities 
or chronic illnesses in the service system. As recommended by the European Commission 
(2009), people with rare diseases, their representatives and patient organisations should 
be consulted and involved in all societal decision-making concerning rare diseases. The 
Council demands the support of work carried out by patient organisations to improve the 
status of people with rare diseases. In the selection criteria, ERN healthcare providers have 
been obligated to cooperate with patient organisations and thus heed the viewpoint of 
people with rare diseases in the planned activities.
The RD-Action project (2014-2018) related to the EU Health Programme deve-
loped a uniform European approach to challenges associated with rare diseases. 
The Patient Empowerment Report (2018) recommends measures for empowe-
ring and engaging people with rare diseases at the national, regional and local le-
vels. In the report, empowerment is a prerequisite to enabling persons with rare 
diseases to promote matters concerning them. Empowerment is associated with 
promoting knowledge, education and necessary support. The empowerment and 
engagement of persons with rare diseases may take place at three different levels:
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Progress in the involvement of persons with rare diseases should be monitored regularly. 
For example, a rare diseases barometer could be designed in cooperation with parties 
working with rare diseases. In such a barometer, especially the objectives set for patient in-
volvement and engagement in this programme could be assessed. 
3.2.1 Empowerment and involvement of people with rare diseases in society 
and their communities
There are dozens of associations and organisation representing people with rare diseases 
in Finland. The Finnish Network for Rare Diseases, consisting of 20 associations, is a natio-
nal cooperation network of various health and social welfare organisations in the field of 
rare diseases. HARSO is an umbrella organisation of associations supporting patients with 
rare diseases and disabilities. Consortiums of organisations and associations lobby matters 
concerning people with rare diseases at the national level. Information on organisations, 
associations and interest groups representing people with rare diseases is available on the 
Finnish Network for Rare Diseases website (www.harvinaiset.fi). Each of these represents its 
target group and lobbies issues important to them and to everyone with rare diseases. Se-
veral receive support from the Funding Centre for Social Welfare and Health Organisations 
(STEA). It channels net revenue from the Finnish gaming company Veikkaus. Enabling sup-
port to small associations and to rare disease patients without any remains challenging.
Individuals with rare diseases are citizens, residents of a municipality, customers and pa-
tients. They and their families need information about their rights, to equitably reach 
appropriate services and to safeguard their lives. Dissemination of information reduces 
prejudices and increases understanding about the full diversity of rare diseases. To boost 
involvement of people with rare diseases, cooperation between Rare Diseases Units, ERN 
centres, patient organisations and other operators in the healthcare and social welfare is 
It is important that as soon as the diagnosis has been made, people with rare diseases 
receive information about their patient organisation, its services and various forms of sup-
port offered. People with rare diseases without an organisation can be advised to contact 
the Finnish Network for Rare Diseases.
1. societal decision-making, prioritisation and development in health and social  
policies
2. planning, implementation, evaluation and development of health and social  
services
3. personal care and service pathways, increased quality of life and holistic wellbeing 
of persons with rare diseases
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required. To disseminate and obtain information, participation of social welfare and heal-
thcare professionals in events organised by patient organisations is vital. Reciprocally, 
people with rare diseases and their families bring their experiential knowledge to dialogue.
Associations and organisations train experts by experience. Their experiential knowledge 
is used in targeted training of professionals, in planning of social welfare and healthcare 
services and assessment of activities. Kokemustoiminta Network consisting of 36 organisa-
tions (www.kokemuskoulutus.fi), cooperates in the briefing and training of experts by 
experience and in communicating experiential knowledge, Associations and organisations 
also train people with rare diseases and their families to be involved, fight for their rights 
and to speak out in contemporary issues. For example, a panel of experts by experience in 
rare diseases (Working Group Harkko) and their family members operates in the Finnish 
Network for Rare Diseases.
The Finnish Network for Rare Diseases conducts yearly surveys to target groups of its 
member communities. The network uses the surveys and the results of Harkko’s work 
when issuing opinions and meeting healthcare and social welfare professionals. Surveys 
and other collection of information should be further strengthened through cooperation 
between healthcare professionals and patient organisations. To support 
lobbying, also HARSO collects information from its member associations. Individual orga-
nisations utilize expert panels (or like) that consist of individuals with rare diseases and 
their family members, enabling discussions on contemporary concerning issues.
 WORKING GROUP HARKKO
 − each of the 20 member communities of the Finnish Network for Rare 
Diseases (FNRD) names 1-2 candidates
 − meets 2-3 times per year
 − the group’s proposals factor in in the development of FNRD activities and 
national lobbying
 − the experts by experience participate in Rare Disease Unit’s steering groups 
and customer panels, and in Harkko meetings
 − matters discussed in the meetings represent general contemporary issues 
related to the status of people with rare diseases and the state of their 
services.
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3.2.2 Involvement of people with rare diseases in developing healthcare 
and social welfare services in their own areas
Enabling people with rare diseases to influence the content of healthcare and social wel-
fare services provided by their own hospital or municipality plays a central role in involve-
ment. The care and service pathways and service contents should be created in coopera-
tion with people with rare diseases. People with rare diseases should be able to moot their 
own needs and experiences into the development and assessment of services routinely. 
Consequently, our service system should adapt to changing demands according to given 
feedback and customer satisfaction.
Some Rare Diseases Units have selected representatives of people with rare diseases into 
their steering groups. Such involvement of people with rare diseases and patient organi-
sations should in all units be harmonised and strengthened. Healthcare professionals are 
responsible for bringing up issues in which rare disease representatives may utilize their 
 OBJECTIVES AND PROPOSED ACTIONS:
 − to encourage and direct individuals with rare diseases to contact relevant 
organisations and to seek peer support and other available services
 − to disseminate information on patient associations and organisations to healthcare 
and social welfare professionals and population in general
 − to promote regional and local engagement and involvement of people with rare 
diseases through the help of patient organisations and regional operators
 − to plan and implement annual Rare Diseases Days in specific catchment areas, 
organised jointly by the Rare Diseases Units and patient organisations 
 − to share experiential knowledge during national and regional training days and fairs 
organised for social welfare and healthcare professionals, with the National Institute 
for Health and Welfare, the Rare Diseases Units and patient organisations
 − to highlight the challenges faced by people with rare diseases in Vammaisfoorumi 
and the Advisory Board for the Rights of Persons with Disabilities (VANE) 
 − to safeguard the operation of associated patient organisations 
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experiential knowledge to improve activities. To enable a genuine and mutual dialogue 
between professionals and rare disease representatives, issues discussed must be intelli-
gible.
Activities in Rare Diseases Units utilise the knowledge of experts by experience. In addi-
tion, units have organised events and other forms of cooperation with rare disease repre-
sentatives and organisations. Open access events should be organised regularly in varying 
locations and planned in cooperation with patient organisations. People with and patient 
organisations for rare diseases find the activities of Rare Disease Units important; there is 
need for stronger reciprocal engagement. The voice of rare disease patients should be 
amplified by customer panels in the units and, for example, by developing feedback 
systems that assess unit activities. Shared views on which unit activities should be elabo-
rated together with rare disease representatives are needed. Shared matters could include 
ensuring operational efficiency of care and service paths or issues related to encounters 
between healthcare or social welfare professionals and people with rare diseases:
The roles of people with and patient organisations for rare diseases need to be strengthened 
in activities of national ERN centres (healthcare providers). In the report on the integration 
of the European Reference Networks into the national healthcare systems (2018), Eurordis 
proposed that customer panels consisting of representatives of the patient organisations 
in the centre’s target group would be established in connection with the centres. A national 
customer panel would correspond to the European Patient Advocacy Groups (ePAG) establis-
hed in the European Reference Networks, playing important roles in the networks activities. 
Between national ERN centres, a systematic cooperation model is called for, with strong rep-
resentation of people with and patient organisations for rare diseases. 
 RARE DISEASE CUSTOMER PANELS
 − to establish customer panels to ERN centres and/or university hospitals
 − to invite representatives of patient organisations, experts by experience, their 
family members and other actors in rare diseases to customer panels
 − to strengthen the role of customer panels in communicating needs and 
wishes of people with rare diseases and in planning and assessment of unit 
activities
 − to utilise in customer panels the experience and expertise of organisations 
and networks like the Finnish Network for Rare Diseases and HARSO 
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3.2.3 Safeguarding the involvement of people with rare diseases in their 
care and services
The involvement of people with rare diseases in the planning and implementation of their 
care and services should be strengthened and their right to self-determination taken into 
account. Many people with rare diseases feel vulnerable, particularly in situations when 
the professional taking care of them does not possess sufficient knowledge about the di-
sease or about patients’ right to choose their place of care, or if the professional has nega-
tive or belittling attitudes towards them or their disease. The prerequisite for stronger in-
volvement of persons with rare diseases in implementation of his or her care and services 
 OBJECTIVES AND PROPOSED ACTIONS:
 − to strengthen the involvement of people with rare diseases by establishing 
customer panels (CP) in university hospitals. CPs will convene regularly to 
plan and to assess contemporary issues related to healthcare and social 
welfare services in rare diseases, together with Rare Diseases Units, centres 
of expertise and other actorsto reach shared apprehension of matters to be 
discussed with experts by experience 
 − to plan and develop the care and service pathways of people with rare 
diseases jointly with healthcare and social welfare professionals, and patient 
organisations.
 − to boost cooperation and communication by Rare Diseases Units to 
healthcare, social welfare and other professionals working with rare diseases, 
and to general public
 − to establish regular dialogue by Rare Disease Units and patient organisations 
to the Social Insurance Institution of Finland (Kela), notably about issues 
concerning rehabilitation, disability benefits and competitive tendering of 
services 
 − to organise in all university hospitals regular annual events directed at patient 
organisations and people with rare diseases 
 − to establish and develop patient feedback systems of the Rare Disease Units 
and ERN centres (healthcare providers): development of electronic feedback 
system as part of services
 − to define the roles of patient organisations and representatives in the 
operation of the ERN healthcare providers already during the application 
process
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is that sufficient information on the health, social and rehabilitation services available. At 
best, patient involvement will be achieved through an equal dialogue and cooperation 
between the professionals and the individuals with rare diseases. When supporting daily 
lives of persons with rare diseases, attention must also be paid to their social milieu inclu-
ding family members, close friends and work communities.
Orderliness of rare disease care and services support individuals’ daily life. Under the Social 
Welfare Act (1301/2014, section 39), a client plan for assessing the need for services must 
be drawn up for the client. Furthermore, a plan for examinations, care, medical rehabilita-
tion and other corresponding activities is mentioned in the Act on the Status and Rights of 
Patients (785/1992, section 4a). Such a plan must be drawn up during the implementation 
of healthcare and medical care, and must indicate the treatment and its implementation 
schedule. The importance of patient involvement and the right to self-determination are 
emphasised by the fact that the plan must be designed in mutual understanding with the 
patient, family member, close friend or legal representative.
3.3  Coordination of activities related to rare diseases
Awareness of rare diseases has increased since the publication of the first National Pro-
gramme. The general public as well as professionals have become increasingly interested 
in rare diseases and the status of people suffering from these. The public, third and com-
pany sectors and the media have all shown interest in people living with rare diseases. Ho-
wever, the multi-layered information, expertise and activities related to rare diseases are 
challenging to master.
 OBJECTIVES AND PROPOSED ACTIONS:
 − to increase guidance, advice and information about the services available 
provided by professionals to persons with rare diseases and about the status 
of patients and clients in healthcare and social welfare 
 − to develop and strengthen group peer support through cooperation between 
patient organisations and healthcare
 − to increase and disseminate information about advisory and peer support 
services provided by patient organisations and associations
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3.3.1 National coordination
The establishment of a national coordinating centre was proposed in the first National 
Programme none has been implemented. Some coordination has been performed by the 
Working Group on Rare Diseases and its Subcommittee. One of the tasks of the current 
Working Group is to propose a model for national coordination.
During the update of the National Programme, our understanding of the importance of 
national coordination in the development of care and comprehensive support of people 
with rare diseases has been reinforced. In the surveys conducted, rare disease associations, 
the Rare Diseases Units and ERN centres all supported the establishment of a coordina-
tion centre almost unanimously. The importance of national coordination was stressed in 
many of the speeches held in the National Conference on Rare Diseases in autumn 2018. 
A variety of tasks have been proposed for the coordinating centre, including gathering in-
formation on rare diseases and promoting the networking of operators in the field of rare 
diseases. Tasks could include systems research related to rare diseases and surveys of nee-
ded services, for example by utilising registry data.
Management of the overall status of rare diseases would be improved by a national da-
tabase tagging rare diseases. Presently, there are occasional registries of individual rare 
diseases or disease groups. The Rare Diseases Units and the National Institute for Health 
and Welfare (THL) are jointly developing the possibility to add not only the ICD-10 but also 
the exact Orpha code to the diagnosis sections of electronic health records. A national 
rare diseases registry would enable to combine the data to EU and ERN registries. Without 
international registries, the diagnostics, care and monitoring of ultra-rare diseases cannot 
be developed adequately. The legislative amendment concerning national THL quality 
registers would permit the creation of such national registry. Table 4 describes various pro-
posals for rare diseases, inclusive of bolstered coordination tasks of THL.
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Table 4. Current or proposed role of different actors in the development and coordination related to rare 
diseases
Ministry of Social Affairs 
and Health
steering of legislation, resources and information, general supervision, assessment, EU cooperati-
on, cooperation in Nordic networks
STEA funding of patient organisation activities in the field of rare diseases, assessment of effectiveness 
of such measures
Healthcare and social wel-
fare
production of services, improving the availability of expertise, agreeing on service pathways and 
referral practices
University Hospital Districts regional cooperation and coordination tasks in accordance with the Centralisation Decree 
(582/2017), information production to Health Village, international research activities, coordinati-
on of centres of expertise and ERN health care providers, care instructions
National Institute for 
Health and Welfare (THL)
information guidance, maintenance of networking, project steering, comprehensive research, as-
sessment and maintenance of services, functioning measures, Orpha codes, knowledge-bases and 
registries
COHERE Finland knowledge steering, assessment of inclusion of services and treatments in rare diseases in the ser-
vice palette of national healthcare
Social Insurance Institution 
of Finland
reimbursement of medicines, costs of cross-border care, other benefits and services, rehabilitation
Fimea, Pharmaceuticals 
Pricing Board (Hila)
marketing authorisation of medicinal products, assessment of benefits to treatment from orphan 
drugs, conditions for reimbursement of medicines (Hila)
Finnish Network for Rare 
Diseases
to influence matters promotion of joint lobbying of organisations, communication, compiling and 
disseminating information
HARSO promotion of organisations’ joint activities to influence matters
Norio Centre of Rare 
Diseases
maintenance of the Finnish Orphanet website, international cooperation
Furthermore, once general agreements on national rehabilitation policies have been 
reached, the development of rehabilitation for rare diseases should be implemented 
through cooperation between university hospitals, Kela and others. Presently, multiple 
operators participate in the coordination of guidance, supervision, regulation and respon-
sibilities in rare diseases. Nevertheless, coordination of these activities to avoid overlaps 
is lacking. Neither can operators monitor equitable implementation of medical and social 
welfare services nationwide, and the interconnectedness of current operators needs imp-
rovements. Also, principles guiding the division of labour between the Rare Diseases Units 
and ERN healthcare providers require national cooperation. 
After systematic assessment of tasks of various operators and the potential to develop 
national coordination in rare diseases, the Working Group proposes that national coordi-
nation of rare diseases should be assigned to the National Institute for Health and Welfare 
(THL). By its assessment THL would be best positioned to coordinate cooperation between 
experts, service providers, patient representatives and the third sector operating in the 
field. It would also be able to coordinate the communication of reliable information. THL is 
also responsible for the maintenance of necessary coding systems and definitions, has the 
capacity to promote registries, collection and analysis of information, and research and 
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development at the national and international levels. Besides ensuring the required 
statutory basis, the Ministry of Social Affairs and Health should continue to bear the main 
responsibility for international cooperation, especially at the level of EU.
Diversity and characteristics of rare diseases require special attention with regard to or-
phan drugs. Special characteristics of pharmacotherapies in rare diseases should be cate-
red to the currently ongoing implementation of rational pharmacotherapy plan and asso-
ciated legislative amendments (Ruskoaho 2019).
The term of the Working Group on Rare Diseases continues until the end of 2019. The 
group will monitor and support the implementation of the National Programme. In accor-
dance with its appointed tasks, it will also give a proposal for the implementation of natio-
nal coordination.
 OBJECTIVES AND PROPOSED ACTIONS:
 − clarification of national coordination and division of labour between the Ministry 
of Social Affairs and Health, THL and service providers
 − university hospitals will strengthen regional coordination in the field of 
rare diseases according to the obligations of the Health Care Act and the 
Centralisation Decree: more detailed description of mutual cooperation and 
division of labour, strengthening of expertise
 − integration of ERNs into our service system, cooperation with other centres of 
expertise
 − in addition to disability services, extending the general coordination tasks of 
THL to rare diseases 
 − development of registries and knowledge bases, establishing continuity of 
Orpha coding and other operations of Orphanet
 − to avoid overlap, boost cooperation and networking between the public and 
third sectors 
 − boosting cooperation in rehabilitation between the Rare Disease Units and 
Social Insurance Institution of Finland (Kela) in order to design national plans 
for various rare disease groups
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3.3.2 Regional coordination
University hospitals bear the regional responsibility for, plan and coordinate the preven-
tion, care, diagnostics and rehabilitation of rare diseases. The clinical units and centres of 
expertise responsible for the diagnostics and care provide the services required by people 
with rare diseases in their field of specialisation. If necessary, the services are provided in 
multidisciplinary and multiprofessional cooperation. The tasks of the Rare Diseases Units 
include participation in the coordination of the diagnostics and the range of services pro-
vided to people with rare diseases, advising and referring them to the right experts and 
to the proper care or service pathway, supporting the clarification of the care and service 
pathways in their own specific catchment area, and cooperation with different healthcare 
units, authorities and organisations.
The units’ task is to help create smooth consultation and referral opportunities and to par-
ticipate in the coordination of the care and diagnostics of those patients who have symp-
toms consistent with rare diseases but for whom no diagnosis has been found in basic 
or specialised medical care. Consultation models for improving the diagnostics, care and 
coordination of the care of rare diseases may be developed in the electronic development 
projects in the field of healthcare and social welfare.
University hospitals can establish centres of expertise for groups of rare diseases or gather 
diverse professional working groups, for which they find the required expertise and 
through which they collaborate regionally or nationally with other parties providing care. 
The tasks of the Rare Diseases Units do not include outpatient clinic activities as the 
examinations and care choices are the responsibility of various specialist units of the 
university hospital districts. If necessary, these consult the ERN healthcare providers or 
refer the patients to them. The care of patients in a stable phase can also be implemented 
in other healthcare units in the area, as long as sufficient consultation support is available. 
 OBJECTIVES AND PROPOSED ACTIONS:
 − harmonising the regional operation of the units for rare diseases and  
strengthening the position of the units located in the specific catchment areas
 − establishing and strengthening the cooperation of Rare Diseases Units with 
different healthcare units in their specific catchment areas, both in specialised 
medical care and basic healthcare, and communicating information about the 
Rare Diseases Units and centres of expertise to basic healthcare
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The Rare Diseases Units can be contacted without a formal referral about questions re-
lated to general advice and guidance. The contact details can be found on the websites of 
the hospitals. Advisory services are provided for example in situations in which an indi-
vidual with rare diseases has not received the required services or treatment, or has not 
found information on how to proceed in the personal care and service pathway. Physicians 
also make referrals to the units.
By clarifying the care and service paths of people with rare diseases, units respond to 
the need to streamline diagnostic and care pathways, as proposed in the first National 
Programme. At the same time, they further increase awareness in their own specific ca-
tchment areas. Adequate resources are required to strengthen the cooperation of the Rare 
Diseases Units with basic healthcare, the hospital districts and specific catchment areas, 
social welfare and organisations,
3.3.3 Coordination of care and services of a person with rare diseases
The importance of the planning of care and services is emphasised in situations when 
multidisciplinary services are needed but available information is scarce. A comprehensive 
customer plan makes it possible to provide many people with rare diseases with adequate 
support for smoothly daily life. The expertise of healthcare social workers and rehabili-
tation instructors should also be used when drawing up a plan: a comprehensive plan 
should include both the healthcare and the social welfare services. When drawing up the 
plan, advantage should be taken of the expertise of the Rare Diseases Units, ERN centres, 
organisations and associations, as necessary.
According to the Social Welfare Act (1301/2014, section 42), a case manager must be de-
signated to a client if the client’s need for services is not short-term or temporary. The ob-
jective of the INNOVCare project funded by the EU was to develop structural reforms and 
comprehensive and customer-centred service pathways improving the social support of 
people with rare diseases. The project ended in 2018. It emphasised the importance of a 
case managers supporting people with rare diseases and their families in the coordination 
of the services and in facing the challenges of everyday life. The case manager helps to 
find the local experts, works as a contact person for local and national expertise and gives 
empowering support to persons with rare diseases and the family members. Based on the 
experience gained in the project, consideration should be given to when it is important 
to designate a case manager to a person with rare diseases, in which tasks the role of the 
case manager should be used and how the case manager could best support the person’s 
involvement in his or her care and service pathways.
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3.4 Estimated cost effects of the National Programme
We propose that the harmonisation of the activities of the Rare Diseases Units be inclu-
ded in the National Programme. Currently, different units have varying personnel resour-
ces. Only one of the units has a full-time physician and nurse. If there is a desire to develop 
the activities, it is important to ensure that the units have adequate resources and exper-
tise. To achieve this, we estimate that approximately 1.6 additional person-years would be 
needed for physicians and 0.8 person-years for nurses at the national level. The cost effect 
would be approximately EUR 200,000 per year.
National coordination requires personnel resources in the national coordination unit. 
According to Subcommittee calculations, at least two person-years are required for the 
national coordination tasks, including the communication of information, coordination of 
networks, update and maintenance of the Orpha codes, and Orphanet activities. Resour-
ces are also required for development of the database and the maintenance of registry for 
rare diseases. In total, these amount to EUR 200,000 - 300,000 per year.
The European Commission grants the ERN centres operating in Finland a small amount 
of financial support for ERN activities. For healthcare providers to fulfil the quality requi-
rements for ERN centres, an additional amount between EUR 20,000- 40,000 per year is 
needed, for maintenance of required procedures and quality systems. Participation in an 
ERN uses an input equal to 0.1 person-years for each sub-group in the network. In total, 
there may be up to ten of them. If centres of expertise joined all the 24 ERNs during the 
programme period, the number of Finnish centres would total approximately 30. The to-
tal amount of work would be between 20 and 25 person-years, divided between several 
specialists. The imputed costs are about EUR 2 million per year. It has been estimated that 
an input of less than EUR 1 million is used to maintain the necessary systems in the year a 
centre is established and about half of that in the following years.
 OBJECTIVES AND PROPOSED ACTIONS:
 − planning and piloting a case manager model to ensure seamless care and 
services for those people with rare diseases requiring large numbers of 
services
 − strengthening the position of healthcare social work in the multidisciplinary  
cooperation carried out in the care of rare diseases
 − piloting the use of personal budgets in those rare diseases that require 
diverse services
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Of note, when estimating the costs of the activities in the field of rare diseases, deficien-
cies in diagnostics and care may lead to large amounts of unnecessary costs. Also, the 
costs of an individual treatment may exceed EUR 1 million per year. By investing in exper-
tise, treatment and care decisions based on knowledge gained by studies and flexible ser-
vices enables allocation of costs in the most appropriate way.
3.5 Practical implementation of the National Programme and 
monitoring it
The National Plan for Rare Diseases is based on the principle of equitable access to ap-
propriate treatment, care and services by people with rare diseases. The promotion 
of involvement improves the status of people with rare diseases and implementation of 
their rights. The Rare Diseases Units established to university hospitals play a key role in 
the coordination of the services required by people with rare diseases.
In addition to the promotion of involvement, the National Programme for Rare Diseases 
2019-2023 emphasises the importance of expertise and national coordination. The Mi-
nistry of Social Affairs and Health and the National Institute for Health and Welfare (THL) 
will be key actors in national coordination. THL has been developing national coordination 
of the services for persons with disabilities and the Working Group is of the opinion that 
many tasks in the national rare disease coordination would be suitable for THL. The role of 
THL as a national authority maintaining registries responds to the need for coordination in 
the field of rare diseases. THL has already promoted the introduction of Orpha codes. Ho-
wever, the maintenance of the Orphanet contact point in Finland remains to be solved. For 
its part, the Ministry of Social Affairs and Health focuses on enabling cross-border coope-
ration by promoting involvement in ERNs, enhancing the utilisation of their expertise and 
promoting cooperation between the Nordic countries.
Patient organisations and Rare Diseases Units promote stronger patient involvement. The 
healthcare and social welfare professionals encountering people with rare diseases are in 
key positions to transmit information about available opportunities for people with rare 
diseases to participate in the activities of patient organisations and to access up-to-date 
and high-quality information. The opportunities to disseminate information have impro-
ved in the 2010s. Coordination is needed to increase cooperation and sensible division 
of labour between various information producers. If overlapping work and production of 
information could be avoided, the resources could be used efficiently to facilitate the daily 
life of as many people with rare diseases as possible.
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The implementation of the programme requires all parties to commit themselves to achie-
ving the jointly drawn up objectives. The Working Group did not want to make this Natio-
nal Programme into a detailed list of actions. Instead, the group wanted to describe the 
key principles and objectives guiding decision-making to improve the position of people 
living with rare diseases. As changes are needed in the healthcare and social welfare ser-
vices, cooperation is required between regional and national operators to implement the 
objectives and actions proposed in this programme. In the time when the structure and 
organisation of healthcare and social welfare services is undergoing a major transforma-
tion at the national level, different operators must work together to identify regionally and 
nationally methods to implement the objectives.
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